0.5%溴莫尼定对360°氩激光小梁成形术后眼压峰值的影响。溴莫尼定-氩激光小梁成形术研究组。
Effect of brimonidine 0.5% on intraocular pressure spikes following 360% argon laser trabeculoplasty. The Brimonidine-ALT Study Group.
出版信息
Ophthalmic Surg Lasers. 1995 Sep-Oct;26(5):404-9.
BACKGROUND AND OBJECTIVE
Brimonidine tartrate 0.5%, a topical alpha 2-adrenergic agonist, was administered before and after argon laser trabeculoplasty (ALT) to evaluate its efficacy against postoperative intraocular pressure (IOP) spikes.
PATIENTS AND METHODS
Two randomized, double-masked, vehicle-controlled investigations evaluated four treatment regimens in 471 patients undergoing ALT for glaucoma or ocular hypertension. The combined results are presented.
RESULTS
IOP elevations > or = 10 mm Hg occurred in 1% (1/122) of the patients who received brimonidine before and after ALT; in 2% (2/119) of those receiving brimonidine before and vehicle after; in 1% (1/114) of those receiving vehicle before and brimonidine after; and in 23% (27/116) of those receiving vehicle before and after (P < .001).
CONCLUSION
The brimonidine regimens were generally effective and well-tolerated ocularly and systemically.
背景与目的
0.5%的酒石酸溴莫尼定，一种局部用α2肾上腺素能激动剂，在氩激光小梁成形术（ALT）前后使用，以评估其对抗术后眼压（IOP）升高的疗效。
患者与方法
两项随机、双盲、赋形剂对照研究评估了471例因青光眼或高眼压症接受ALT治疗的患者的四种治疗方案。呈现合并结果。
结果
在ALT前后均接受酒石酸溴莫尼定治疗的患者中，眼压升高≥10 mmHg的发生率为1%（1/122）；在ALT前接受酒石酸溴莫尼定治疗、ALT后接受赋形剂治疗的患者中，发生率为2%（2/119）；在ALT前接受赋形剂治疗、ALT后接受酒石酸溴莫尼定治疗的患者中，发生率为1%（1/114）；在ALT前后均接受赋形剂治疗的患者中，发生率为23%（27/116）（P<0.001）。
结论
酒石酸溴莫尼定治疗方案总体上有效，眼部和全身耐受性良好。
Zotero 插件